PTE - PolarityTE, Inc.
| Previous Close | 2.7300 |
| Open | 2.7400 |
| Bid | 2.6100 x 1400 |
| Ask | 2.6400 x 800 |
| Day's Range | 2.6000 - 2.7400 |
| 52 Week Range | 2.1000 - 18.1700 |
| Volume | 31,419 |
| Avg. Volume | 261,859 |
| Market Cap | 72M |
| Beta (3Y Monthly) | 1.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.6990 |
| Earnings Date | Nov 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2016-01-12 |
| 1y Target Est | 13.17 |
- Business Wire
PolarityTE Builds Patent Portfolio with New International Patent Grants
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that the company has recently been granted a patent in New Zealand and has received approvals for patent applications in the United Kingdom and Australia. The grant of PolarityTE’s Canadian patent was announced in August, bringing the total number of patents and approvals in 2019 to four. These developments demonstrate the momentum of PolarityTE’s ongoing efforts to develop, support and protect its intellectual property.
- Benzinga
12 Biotech Stocks Primed For A Short Squeeze
Biotech investment is fraught with risk. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts. These binary events , however, provide an opportunity for making ...
- Business Wire
PolarityTE Announces Equity Purchase Agreement for up to $25 Million with Keystone Capital Partners
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it has entered into a $25.0 million equity purchase agreement (the "Agreement") with Keystone Capital Partners, LLC ("Keystone"), a New York-based institutional investor.
- Simply Wall St.
Here's Why We're A Bit Worried About PolarityTE's (NASDAQ:PTE) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Business Wire
PolarityTE to Attend Evercore ISI 2nd Annual HealthCONx Conference and Piper Jaffray 31st Annual Healthcare Conference
PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will attend the Evercore ISI HealthCONx Conference on Tuesday, December 3, 2019 in Boston and the Piper Jaffray 31st Annual Healthcare Conference on Wednesday, December 4, 2019 in New York, NY.
- PR Newswire
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating PolarityTE, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK , Nov. 19, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...
- Business Wire
PolarityTE Reports Third Calendar Quarter 2019 Results
PolarityTE, Inc. , a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today reported financial results for the third calendar quarter of 2019.
- Business Wire
PolarityTE Adopts Short-Term Shareholder Rights Plan
PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that its Board of Directors approved a short-term shareholder rights agreement (“the Rights Agreement”) following an evaluation by the Shareholder Rights Committee established by the Board in August 2019. The Rights Agreement is intended to ensure that all PolarityTE shareholders receive fair treatment in any potential transaction, while allowing the Board and shareholders adequate time to make informed strategic decisions that the Board and the Company’s executive management team are currently evaluating. The Rights Agreement is not intended to deter offers that are fair and otherwise in the best interests of PolarityTE’s shareholders.
- Business Wire
PolarityTE to Report Calendar Third Quarter Financial Results on November 12, 2019
PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will report calendar third quarter 2019 financial results by press release on Tuesday, November 12, 2019 at approximately 4:00 p.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on Tuesday, November 12, 2019 at 4:30 p.m. Eastern Time. The conference call can be accessed by calling 1-866-548-4713 (U.S. and Canada) or +44 (0)330 336 9105 (International) with confirmation code 6761138 and referencing “PolarityTE Third Quarter 2019 Earnings Call.” A webcast of the conference call can be accessed by using the link below.
- Simply Wall St.
PolarityTE, Inc. (NASDAQ:PTE): What Does Its Beta Value Mean For Your Portfolio?
If you're interested in PolarityTE, Inc. (NASDAQ:PTE), then you might want to consider its beta (a measure of share...
- Business Wire
PolarityTE Announces Positive Pilot Study Data of SkinTE as a Treatment for Venous Stasis Leg Ulcers
PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced findings from an open-label, single-arm pilot study, which examined the impact of SkinTE™, a novel human cellular and tissue-based product derived from a patient's own skin, in closing venous stasis leg ulcers (VLUs) following failure of conventional treatments. The clinical outcomes were reported in a poster presentation, entitled Pilot Study Assessing Novel Autologous Homologous Skin Construct Treatment of Venous Stasis Leg Ulcers, at the Symposium on Advanced Wound Care (SAWC) Fall Meeting, held in Las Vegas, October 12-14, 2019.
- GlobeNewswire
Bragar Eagel & Squire is Investigating Certain Officers and Directors of National General Holdings, Natural Health Trends, Omnicell, and Polarity TE and Encourages Investors to Contact the Firm
Bragar Eagel & Squire is investigating certain officers and directors of National General Holdings Corp. (NGHC), Natural Health Trends Corp. (NHTC), Omnicell, Inc. (OMCL), and PolarityTE, Inc. (PTE) on behalf of long-term stockholders. More information about each potential case can be found at the link provided. Bragar Eagel and Squire is investigating certain officers and directors of National General Holdings Corp. following a class action complaint that was filed against National General on July 25, 2019.
- Business Wire
SkinTE Data to be Presented at the 19th Annual Diabetic Foot Global Conference
PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that two abstracts demonstrating the impact of the Company’s SkinTE™ product in treating diabetes-related wounds were accepted for poster presentations at the 2019 Diabetic Foot Global Conference (DFCon), an international, interdisciplinary diabetic foot conference hosted by the Keck School of Medicine of University of Southern California in collaboration with Baylor College of Medicine and University of California San Francisco from October 17-19, 2019 in Los Angeles. Today’s announcement further signifies the Company’s momentum with its clinical research program, bringing the total SkinTE data presentations at medical conference in 2019 to 36, of which 14 were podium presentations.
- PR Newswire
SkinTE Data to be Presented at the American Society of Plastic Surgeons 88th Annual Scientific Meeting
Podium Presentation to Highlight a Variety of SkinTE Clinical Results in Trauma, Wound, and Burn from a 15 Patient Case Series SALT LAKE CITY , Sept. 9, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: ...
- PR Newswire
PolarityTE Appoints Peter Cohen as Chairman of the Board
SALT LAKE CITY, Sept. 4, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced the appointment of Peter Cohen, previously Lead Director, as Chairman of the Board. "It gives me great satisfaction to lead the Board during this important time at PolarityTE. I am proud to be part of a company with such an innovative technology, which not only addresses an unmet medical need, but has the potential to become a mainstay treatment in the field of skin and tissue regeneration," said Mr. Cohen. "There have been growing pains and unexpected challenges in the development of PolarityTE, which can occur with innovative companies, especially those that have the potential to disrupt the biotechnology industry. I am pleased with the strides we have made to address these growing pains and challenges, and believe we have the right, disciplined approach to best position the business for growth.
- PR Newswire
PolarityTE to Attend H.C. Wainwright 21st Annual Healthcare Conference and Morgan Stanley 17th Annual Global Healthcare Conference
SALT LAKE CITY, Aug. 28, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will present at the H.C. Wainwright 21st Annual Healthcare Conference on September 9, 2019 in New York, NY. PolarityTE also announced that it will attend and meet with investors during the Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York, NY. PolarityTE is focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences.
- Simply Wall St.
Introducing PolarityTE (NASDAQ:PTE), The Stock That Tanked 80%
PolarityTE, Inc. (NASDAQ:PTE) shareholders should be happy to see the share price up 11% in the last week. But that...
- PR Newswire
PolarityTE Granted Canadian Patent
SALT LAKE CITY , Aug. 20, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that ...
- PR Newswire
PolarityTE to Present at Military Health System Research Symposium on Platform Technology for Treatment of Traumatic and Chronic Wounds
SALT LAKE CITY, Aug. 16, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will present data on the potential for SkinTE™ and OsteoTE™ to address military-related traumas and chronic wounds at the Military Health System Research Symposium on August 21, 2019, in Kissimmee, FL. SkinTE is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for the repair, reconstruction and replacement of a patient's own skin. OsteoTE, based on the same platform technology, is an autologous, homologous human cellular and tissue-based product intended to repair, reconstruct, replace and supplement bone.
- PR Newswire
PolarityTE Reports Second Calendar Quarter 2019 Results
SALT LAKE CITY , Aug. 8, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today reported financial ...
